Repositioning Candidate Details
| Candidate ID: | R0243 |
| Source ID: | DB00694 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Daunorubicin |
| Synonyms: | (+)-Daunomycin; (8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; Acetyladriamycin; Daunomycin; Leukaemomycin C; Rubidomycin |
| Molecular Formula: | C27H29NO10 |
| SMILES: | COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O |
| Structure: |
|
| DrugBank Description: | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. |
| CAS Number: | 20830-81-3 |
| Molecular Weight: | 527.5199 |
| DrugBank Indication: | For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin is indicated in combination with for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. |
| DrugBank Pharmacology: | Daunorubicin is an anthracycline antibiotic and antineoplastic agent. It acts by inhibiting cellular reproduction through interference with DNA replication although it may contribute to the induction of cell death by increasing oxidative stress through the generation of reactive oxygen species and free radicals. As an antineoplastic agent, daunorubicin carries significant toxicities including cytopenias, hepatotoxicity, and extravasation reactions. Like other anthracyclines, daunorubicin also exhibits cardiotoxicity in proportion with the cumulative dose received over time. |
| DrugBank MoA: | Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. |
| Targets: | DNA intercalation; DNA topoisomerase 2-alpha inhibitor; DNA topoisomerase 2-beta inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
